Joint Model of Iron and Hepcidin During the Menstrual Cycle in Healthy Women

详细信息    查看全文

• 作者：Adeline Angeli ; Fabrice Lainé ; Audrey Lavenu ; Martine Ropert…
• 刊名：The AAPS Journal
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：18
• 期：2
• 页码：490-504
• 全文大小：1,195 KB
• 参考文献：1.Meynard D, Babitt JL, Lin HY. The liver: conductor of systemic iron balance. Blood. 2014;123:168–76.CrossRef PubMed PubMedCentral
  2.Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93:1721–41.CrossRef PubMed
  3.Dunn LL, Suryo Rahmanto Y, Richardson DR. Iron uptake and metabolism in the new millenium. Trends Cell Biol. 2006;17:93–100.CrossRef PubMed
  4.Anderson GJ, Vulpe CD. Mammalian iron transport. Cell Mol Life Sci. 2007;66:3241–61.CrossRef
  5.Anderson GJ, Frazer DM, McLaren GD. Iron absorption and metabolism. Curr Opin Gastroenterol. 2009;25:129–35.CrossRef PubMed
  6.Mariani R, Trombini P, Pozzi M, Piperno A. Iron metabolism in thalassemia and sickle cell disease. Mediterr J Hematol Infect Dis. 2009;1:e2009006.PubMed PubMedCentral
  7.Loréal O, Haziza-Pigeon C, Troadec MB, Devitaud L, Turlin B, Courselaud B, et al. Hepcidin in iron metabolism. Curr Protein Pept Sci. 2005;6:279–91.CrossRef PubMed
  8.Linder MC. Mobilization of stored iron in mammals: a review. Nutrients. 2013;5:4022–50.CrossRef PubMed PubMedCentral
  9.Kim I, Yetley EA, Calvo MS. Variations in iron-status measures during the menstrual cycle. Am J Clin Nutr. 1993;58:705–9.PubMed
  10.Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Am Soc Hematol. 2011;117:218–25.
  11.Lainé F, Laviolle B, Ropert M, Bouguen G, Morcet J, Hamon C, et al. Early effects of erythropoietin on serum hepcidin and serum iron bioavailability in healthy volunteers. Eur J Appl Physiol. 2011;112:1391–7.CrossRef PubMed
  12.Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell. 2010;142:24–38.CrossRef PubMed
  13.Ruivard M, Lainé F, Ganz T, Olbina G, Westerman M, Nemeth E, et al. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol. 2009;50:1219–25.CrossRef PubMed
  14.Zhang AS, Enns CA. Molecular mechanisms of normal iron homeostasis. Am Soc Hematol. 2009;1:207–14.CrossRef
  15.Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271–6.CrossRef PubMed PubMedCentral
  16.Higham JM, O’Brien PM, Shaw RM. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990;97:734–9.CrossRef PubMed
  17.Bazzoli C, Retout S, Mentré F. Design evaluation and optimization in multiple response nonlinear mixed effect models: PFIM 3.0. Comput Methods Prog Biomed. 2010;98:55–65.CrossRef
  18.Retout S, Comets E, Samson A, Mentré F. Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates. Stat Med. 2007;26:5162–79.CrossRef PubMed
  19.Xiao JJ, Krzyzanski W, Wang YM, Li H, Rose MJ, Ma M, et al. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J. 2010;12:646–57.CrossRef PubMed PubMedCentral
  20.Davidian M, Giltinan DM. Nonlinear models for repeated measurement data. London, UK: Chapman and Hall; 1995.
  21.Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal. 2005;49:1020–38.CrossRef
  22.Lavielle M. MONOLIX (MOdèles NOn LInéaires à Effets MiXtes). France: INRIA, Orsay; 2014. http://www.lixoft.eu/wp-content/resources/docs/UsersGuide.pdf . Accessed 25 Oct 2015.
  23.Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther. 1994;56:406–19.CrossRef PubMed
  24.Gabrielsson J, Weiner D, eds. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. Swedish Pharmaceutical Press; 2007.
  25.Wakelkamp M, Alván G, Gabrielsson J, Paintaud G. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin Pharmacol Ther. 1996;60:75–88.CrossRef PubMed
  26.Fattinger K, Verotta D, Benowitz NL. Pharmacodynamics of acute tolerance to multiple nicotinic effects in humans. J Pharmacol Exp Ther. 1997;281:1238–46.PubMed
  27.Brendel K, Comets E, Laffont C, Laveille C, Mentré F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23:2036–49.CrossRef PubMed PubMedCentral
  28.Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Prog Biomed. 2008;90:154–66.CrossRef
  29.Troadec MB, Lainé F, Daniel V, Rochcongar P, Ropert M, Cabillic F, et al. Daily regulation of serum and urinary hepcidin is not influenced by submaximal cycling exercise in humans with normal iron metabolism. Eur J Appl Physiol. 2009;106:435–43.CrossRef PubMed
  30.Milman N, Rosdahl N, Lyhne N, Jorgensen T, Graudal N. Iron status in Danish women aged 35-65 years. Relation to menstruation and method of contraception. Acta Obstet Gynecol Scand. 1993;72:601–5.CrossRef PubMed
  31.Milman N. Serum ferritin in Danes: studies of iron status from infancy to old age, during blood donation and pregancy. Int J Hematol. 1996;63:103–35.CrossRef PubMed
  32.Sharma A, Ebling WF, Jusko WJ. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci. 1998;87:1577–84.CrossRef PubMed
  33.Harvey LJ, Armah CN, Dainty JR, Foxall RJ, John Lewis D, Langford NJ, et al. Impact of menstrual blood loss and diet on iron deficiency among women in the UK. Br J Nutr. 2005;94:557–64.CrossRef PubMed
  34.Greig AJ, Palmer MA, Chepulis LM. Hormonal contraceptive practices in young Australian women (≤25 years) and their possible impact on menstrual frequency and iron requirements. Sex Reprod Health. 2010;1:99–103.CrossRef
  35.Milman N, Clausen J, Byg KE. Iron status in 268 Danish women aged 18-30 years: influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol. 1998;77:13–9.CrossRef PubMed
  36.Hamza RT, Hamed AI, Kharshoum RR. Iron homeostasis and serum hepcidin-25 levels in obese children and adolescents: relation to body mass index. Horm Res Paediatr. 2013;80:11–7.PubMed
  37.Cheng HL, Bryant CE, Rooney KB, Steinbeck KS, Griffin HJ, Petocz P, et al. Iron, hepcidin and inflammatory status of young healthy overweight and obese women in Australia. Plos One. 2013;8:e68675.CrossRef PubMed PubMedCentral
  38.Kim A, Nemeth E. New insights into iron regulation and erythropoiesis. Curr Opin Hematol. 2015;22:199–205.CrossRef PubMed
  39.Sany D, Elsawy AE, Elshahawy Y. Hepcidin and regulation of iron homeostasis in maintenance hemodialysis patients. Saudi J Kidney Dis Transpl. 2014;25:967–73.CrossRef PubMed
  40.Guo X, Zhou D, An P, Wu Q, Wang H, Wu A, et al. Associations between serum hepcidin, ferritin and Hb concentrations and type 2 diabetes risks in a Han Chinese population. Br J Nutr. 2013;110:2180–5.CrossRef PubMed
  41.Bergamaschi G, Villani L. Serum hepcidin: a novel diagnostic tool in disorders of iron metabolism. J Hematol. 2009;94:1631–3.CrossRef
  42.Kroot JJC, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin Chem. 2011;57:1650–69.CrossRef PubMed
  43.Lainé F, Angeli A, Ropert M, Jezequel C, Bardou-Jacquet E, Deugnier Y, et al. Variations of hepcidin and iron-status parameters during menstrual cycle in healthy women. Br J Haematol. 2015.
  
• 作者单位：Adeline Angeli (1)
  Fabrice Lainé (1) (2) (3)
  Audrey Lavenu (1) (4)
  Martine Ropert (2) (3)
  Karine Lacut (5)
  Valérie Gissot (6)
  Sylvie Sacher-Huvelin (7) (8)
  Caroline Jezequel (1) (3)
  Aline Moignet (1) (3)
  Bruno Laviolle (1) (3) (4)
  Emmanuelle Comets (1) (10) (4) (9)
  
  1. INSERM CIC 1414, Rennes, France
  2. INSERM U991, Rennes, France
  3. CHU, Rennes, France
  4. University Rennes 1, Rennes, France
  5. INSERM CIC 1412, Brest, France
  6. INSERM CIC 1415, Tours, France
  7. INSERM CIC 1413, Nantes, France
  8. IMAD, CHU Hotel Dieu, Nantes, France
  10. Université Paris Diderot, Sorbonne Paris Cité, Paris, France
  9. INSERM IAME UMR 1137, Paris, France
  
• 刊物主题：Pharmacology/Toxicology; Biochemistry, general; Biotechnology; Pharmacy;
• 出版者：Springer US
• ISSN：1550-7416

文摘

Hepcidin regulates serum iron levels, and its dosage is used in differential diagnostic of iron-related pathologies. We used the data collected in the HEPMEN (named after HEPcidin during MENses) study to investigate the joint dynamics of serum hepcidin and iron during the menstrual cycle in healthy women. Ninety menstruating women were recruited after a screening visit. Six fasting blood samples for determination of iron-status variables were taken in the morning throughout the cycle, starting on the second day of the period. Non-linear mixed effect models were used to describe the evolution of iron and hepcidin. Demographic and medical covariates were tested for their effect on model parameters. Parameter estimation was performed using the SAEM algorithm implemented in the Monolix software. A general pattern was observed for both hepcidin and iron, consisting of an initial decrease during menstruation, followed by a rebound and stabilising during the second half of the cycle. We developed a joint model including a menstruation-induced decrease of both molecules at the beginning of the menses and a rebound effect after menses. Iron stimulated the release of hepcidin. Several covariates, including contraception, amount of blood loss and ferritin, were found to influence the parameters. The joint model of iron and hepcidin was able to describe the fluctuations induced by blood loss from menstruation in healthy non-menopausal women and the subsequent regulation. The HEPMEN study showed fluctuations of iron-status variables during the menstrual cycle, which should be considered when using hepcidin measurements for diagnostic purposes in women of child-bearing potential.